Effectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis

Our study aimed to investigate the effectiveness and safety of botulinum toxin type A in patients with restless legs syndrome. We searched electronic databases, including PubMed, Cochrane Library, and Web of Science, up to 12 June 2021, for published articles. We enrolled randomized controlled clini...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu-Chi Su, Yao-Hong Guo, Chung-Lun Liao, Yu-Ching Lin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	botulinum toxin restless legs syndrome systematic review meta-analysis Medicine R
Acceso en línea:	https://doaj.org/article/b16aa0f1380849e08e511167bc64228a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b16aa0f1380849e08e511167bc64228a
record_format	dspace
spelling	oai:doaj.org-article:b16aa0f1380849e08e511167bc64228a2021-11-25T17:45:51ZEffectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis10.3390/healthcare91115382227-9032https://doaj.org/article/b16aa0f1380849e08e511167bc64228a2021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9032/9/11/1538https://doaj.org/toc/2227-9032Our study aimed to investigate the effectiveness and safety of botulinum toxin type A in patients with restless legs syndrome. We searched electronic databases, including PubMed, Cochrane Library, and Web of Science, up to 12 June 2021, for published articles. We enrolled randomized controlled clinical trials and non-randomized controlled studies involving patients with restless legs syndrome who were treated with botulinum toxin. Quality assessment was performed using the Cochrane risk of bias tool and Joanna Briggs Institute Critical Appraisal Checklist for Quasi-Experimental Studies. As for the results, we included four articles comprising 62 participants, two studies were randomized controlled trials. Improvement in International Restless Legs Syndrome Study Group (IRLSSG) rating scale was observed in three studies. Adverse events were temporary and self-limited. Meta-analyses were performed, including the two randomized controlled trials with 27 participants. Compared with placebo, botulinum toxin injection significantly reduced scores of IRLSSG rating scale (SMD, −0.819, 95% confidence interval [CI], −1.377 to −0.262). A total of 11.8% (95% CI, 0.7–72.4%) of patients reported at least one adverse event. In conclusion, botulinum toxin injection may relieve restless legs syndrome related symptoms. However, decisive conclusions cannot be drawn because of the small number of patients included in our meta-analysis. Large-scale, randomized controlled trials are warranted to discover the optimal dose, safety, and long-term effect of intervention with botulinum toxin type A for patients with restless legs syndrome.Yu-Chi SuYao-Hong GuoChung-Lun LiaoYu-Ching LinMDPI AGarticlebotulinum toxinrestless legs syndromesystematic reviewmeta-analysisMedicineRENHealthcare, Vol 9, Iss 1538, p 1538 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	botulinum toxin restless legs syndrome systematic review meta-analysis Medicine R
spellingShingle	botulinum toxin restless legs syndrome systematic review meta-analysis Medicine R Yu-Chi Su Yao-Hong Guo Chung-Lun Liao Yu-Ching Lin Effectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis
description	Our study aimed to investigate the effectiveness and safety of botulinum toxin type A in patients with restless legs syndrome. We searched electronic databases, including PubMed, Cochrane Library, and Web of Science, up to 12 June 2021, for published articles. We enrolled randomized controlled clinical trials and non-randomized controlled studies involving patients with restless legs syndrome who were treated with botulinum toxin. Quality assessment was performed using the Cochrane risk of bias tool and Joanna Briggs Institute Critical Appraisal Checklist for Quasi-Experimental Studies. As for the results, we included four articles comprising 62 participants, two studies were randomized controlled trials. Improvement in International Restless Legs Syndrome Study Group (IRLSSG) rating scale was observed in three studies. Adverse events were temporary and self-limited. Meta-analyses were performed, including the two randomized controlled trials with 27 participants. Compared with placebo, botulinum toxin injection significantly reduced scores of IRLSSG rating scale (SMD, −0.819, 95% confidence interval [CI], −1.377 to −0.262). A total of 11.8% (95% CI, 0.7–72.4%) of patients reported at least one adverse event. In conclusion, botulinum toxin injection may relieve restless legs syndrome related symptoms. However, decisive conclusions cannot be drawn because of the small number of patients included in our meta-analysis. Large-scale, randomized controlled trials are warranted to discover the optimal dose, safety, and long-term effect of intervention with botulinum toxin type A for patients with restless legs syndrome.
format	article
author	Yu-Chi Su Yao-Hong Guo Chung-Lun Liao Yu-Ching Lin
author_facet	Yu-Chi Su Yao-Hong Guo Chung-Lun Liao Yu-Ching Lin
author_sort	Yu-Chi Su
title	Effectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis
title_short	Effectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis
title_full	Effectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis
title_fullStr	Effectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis
title_full_unstemmed	Effectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis
title_sort	effectiveness and safety of botulinum toxin type a in treatment of restless legs syndrome: a systematic review and meta-analysis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b16aa0f1380849e08e511167bc64228a
work_keys_str_mv	AT yuchisu effectivenessandsafetyofbotulinumtoxintypeaintreatmentofrestlesslegssyndromeasystematicreviewandmetaanalysis AT yaohongguo effectivenessandsafetyofbotulinumtoxintypeaintreatmentofrestlesslegssyndromeasystematicreviewandmetaanalysis AT chunglunliao effectivenessandsafetyofbotulinumtoxintypeaintreatmentofrestlesslegssyndromeasystematicreviewandmetaanalysis AT yuchinglin effectivenessandsafetyofbotulinumtoxintypeaintreatmentofrestlesslegssyndromeasystematicreviewandmetaanalysis
_version_	1718412066169028608

Effectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis

Ejemplares similares